PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity

PHASE2RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

November 21, 2023

Primary Completion Date

November 21, 2026

Study Completion Date

December 31, 2027

Conditions

Inborn Errors of Immunity

Interventions

DRUG

Cyclophosphamide

Cyclophosphamide 25mg/kg (days +3, +4) after HSCT from MUD and MRD Cyclophosphamide 50mg/kg (days +3, +4) after HSCT from MMRD

DRUG

Ruxolitinib

Ruxolitinib 7 mg/m2 from day +5 after HSCT

Trial Locations (1)

RECRUITING

HSCT department, Moscow

All Listed Sponsors

lead

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

OTHER